Conception
Bianka Seres has a diverse work experience in the field of reproductive health. Bianka started their career in 2010 as a Clinical Embryologist at OXFORD FERTILITY LIMITED, where they worked until 2014. Bianka then joined Bourn Hall Fertility Clinic as a Research Scientist in 2016, and remained in this role until 2018. Bianka currently holds the position of Head of Engineering and COO at Conception since April 2019.
Bianka Seres has a diverse education history in the field of Biological Sciences and Clinical Embryology. Bianka has completed a Doctor of Philosophy (PhD) in Biological Sciences from the University of Cambridge. Additionally, they have pursued a Doctor of Philosophy - PhD (year 2-3 of PhD) at the Max Planck Institute for Biophysical Chemistry in Goettingen, Germany, with a focus on the Department Schuh and Meiosis.
Furthering their expertise, Bianka has obtained a Master of Science (MSc) in Clinical Embryology from the University of Oxford, specifically from the Nuffield Department of Women's & Reproductive Health. During their education, they conducted an MSc dissertation under the guidance of the Zernicka-Goetz lab at The Gurdon Institute in Cambridge, UK, specializing in Clinical Embryology.
Bianka also holds a Bachelor of Science (BSc) in Biomedical Sciences from the University of Westminster. In addition to their formal education, they have received a Post Graduate Certificate from the Association of Clinical Embryologists (ACE), though the specific details regarding when they obtained this certification are not provided.
This person is not in the org chart
Conception
Conception is a company developing the technology to turn skin cells into viable human eggs.This technology will give women the opportunity to have children well into their forties and fifties, eliminate barriers for couples suffering from infertility, and potentially allow male-male couples to have biological children.Long term, thistechnology could be a critical platform allowing for widespread genetic screening of embryos. If proven safe, it could even enable for genetic editing to eliminate and reduce the risk of devastating diseases for future generations – such as Alzheimer’s, heart disease and many different types of cancers.This could become one of the most important technologies ever created.The company was founded in 2018 and is headquartered in Berkeley, California.